Here are the general guidelines: Pexate is given as an intravenous infusion over 10 minutes on the first day of each 21-day treatment cycle
Our eCLIP data indicate binding of NS3 to 5BSL3.1 and 5BSL3.3, while our AF3 prediction of the interaction suggests such a complex could help display 5BSL3.2, a hub of interactions regulating HCV (+) strand functions
The L-Glutathione used is of high-purity, fermentative quality
This educational page outlines a short subcutaneous cycle with a dilution chosen so doses land on easy-to-read insulin-syringe marks
Poster Session II - ACUTE ISCHEMIC STROKE MANAGEMENT 01.00 - ACUTE ISCHEMIC STROKE MANAGEMENT - 01.03 - HYPERACUTE MANAGEMENT P667 - ESOC25-2238 DIAGNOSTIC ACCURACY OF POINT-OF-CARE VISCOELASTIC ASSESSMENT OF DIRECT ORAL ANTICOAGULATION IN ACUTE ISCHEMIC STROKE: INTERIM RESULTS FROM A PROSPECTIVE VALIDATION STUDY Annahita Sedghi 1 , Eva Meyer-Bender 1 , Lars Heubner 2 , Joerg Pietsch 3 , Oliver Tiebel 4 , Kristian Barlinn 1 , Jan Beyer-Westendorf 5 , Volker Puetz 1 , Peter Spieth 2 , Timo Siepmann 1 1 Dresden Neurovascular Center, Department of Neurology, Medical Faculty and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany, 2 Department of Anesthesiology and Intensive Care Medicine, Medical Faculty and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany, 3 Institute of Legal Medicine, Medical Faculty and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany, 4 Institute of Clinical Chemistry, Medical Faculty and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany, 5 Thrombosis Research Unit, Department of Medicine I, Medical Faculty and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany Background and Aims: Intravenous thrombolysis in patients with acute ischemic stroke (AIS) is often delayed because of uncertainty about the presence of direct oral anticoagulants (DOACs)
Background: FMDs significantly impact patients' lives, yet their experiences remain poorly understood
